Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/35830
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTurgeon G.-A.en
dc.contributor.authorSolomon B.en
dc.contributor.authorAzad A.A.en
dc.contributor.authorWeickhardt A.en
dc.contributor.authorSiva S.en
dc.date.accessioned2021-05-14T12:07:35Zen
dc.date.available2021-05-14T12:07:35Zen
dc.date.copyright2019en
dc.date.created20190130en
dc.date.issued2019-01-30en
dc.identifier.citationMedical Journal of Australia. 210 (1) (pp 47-53), 2019. Date of Publication: January 2019.en
dc.identifier.issn0025-729Xen
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/35830en
dc.description.abstract* Radiotherapy is an effective treatment modality commonly used in efforts to cure many localised cancers and in the palliation of symptoms in metastatic cancers. * Immunotherapy has revolutionised cancer care by increasing the disease control and overall survival of patients in several cancer types; however, the majority of patients do not respond to currently available therapies based on immune checkpoint inhibitors (ICIs). The benefit of those agents is limited to patients who have a preexisting active immune microenvironment that can be reactivated by ICIs. * It is now recognised that radiotherapy does not only directly kill tumour cells but it also changes the tumour microenvironment, enhancing tumour cell recognition by the immune system and, therefore, acting as an in situ vaccine. * Radiotherapy increases expression of tumour-associated antigens, causes the release of cytokines, stimulates recruitment of dendritic cells and, most importantly, stimulates the proliferation and priming of cytotoxic CD8+ T cells in the tumour microenvironment. This immunological cascade specifically generates activated T cells able to induce immunogenic cell death directed against cancer cells bearing those antigens. * By its ability to overcome some tumour immune escape mechanisms, radiation provides a non-pharmacological and cost-effective approach to potentially improve the systemic response to immune checkpoints inhibitors.Copyright © 2018 AMPCo Pty Ltd.en
dc.languageenen
dc.languageEnglishen
dc.publisherAustralasian Medical Publishing Co. Ltd (E-mail: ampco@ampco.com.au)en
dc.relation.ispartofMedical Journal of Australiaen
dc.titleRadiotherapy and immunotherapy: A synergistic effect in cancer care.en
dc.typeReviewen
dc.type.studyortrialReview article (e.g. literature review, narrative review)-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.5694/mja2.12046en
dc.publisher.placeAustraliaen
dc.identifier.pubmedid30636308 [http://www.ncbi.nlm.nih.gov/pubmed/?term=30636308]en
dc.identifier.source626053169en
dc.identifier.institution(Turgeon, Solomon, Siva) Peter MacCallum Cancer Institute, Melbourne, VIC, Australia (Weickhardt) Olivia Newton-John Cancer Centre, Austin Health, Melbourne, VIC, Australia (Weickhardt) La Trobe University, Melbourne, VIC, Australia (Azad) Monash Health, Melbourne, VIC, Australia (Azad) Monash University, Melbourne, VIC, Australia (Siva) University of Melbourne, Melbourne, VIC, Australiaen
dc.description.addressS. Siva, Peter MacCallum Cancer Institute, Melbourne, VIC, Australia. E-mail: Shankar.Siva@petermac.orgen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2019 Elsevier B.V., All rights reserved.en
dc.identifier.authoremailSiva S.; Shankar.Siva@petermac.orgen
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.openairetypeReview-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
Appears in Collections:Articles
Show simple item record

Page view(s)

26
checked on Sep 17, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.